Form 4: VolitionRx Director Alan Colman Receives Stock Award in Lieu of Cash Compensation

Director Alan Colman received 12,016 restricted stock units (RSUs) from VolitionRx Ltd in lieu of cash compensation on June 1, 2024.

Summary

• On June 1, 2024, Alan Colman, a director of VolitionRx Ltd, was granted 12,016 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan.
• The RSUs were awarded in place of cash compensation that would have otherwise been paid to Mr. Colman.
• The RSUs vest in three installments: 4,006 units on June 1, 2024, 4,005 units on July 1, 2024, and 4,005 units on August 1, 2024.
• The RSUs are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting and settlement, Mr. Colman will receive shares of common stock equal to the number of RSUs that have vested.
• Following the transaction, Mr. Colman beneficially owns 198,795 shares of VolitionRx Ltd.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction of awarding stock to a director. There's no indication of positive or negative implications for the company's performance.

Positives

• The acceptance of RSUs in lieu of cash compensation may indicate a belief in the future value of the company's stock by the director.
• The vesting schedule incentivizes continued service by the director.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs suggests an expectation of continued service from the director.

Industry Context

This type of equity compensation is common for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the biotechnology industry.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize stock options and restricted stock units to compensate and incentivize their directors.
• The size of the RSU grant is likely determined by factors such as the director's role, company size, and overall compensation strategy, and would need to be compared to peer companies to assess its relative value.

Stakeholder Impact

• The granting of RSUs aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
• The dilution effect of the RSUs on existing shareholders is likely minimal.

Key Dates